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Abstract
Background: Neoadjuvant chemoradiotherapy followed by surgery is the mainstay treatment for locally advanced
rectal cancer, leading to significant decrease in tumor size (downsizing) and a shift towards earlier disease stage
(downstaging). Extensive histopathological work-up of the tumor specimen after surgery including tumor regression
grading and lymph node status helped to visualize individual tumor sensitivity to chemoradiotherapy,
retrospectively. As the response to neoadjuvant chemoradiotherapy is heterogeneous, however, valid biomarkers
are needed to monitor tumor response. A relevant number of studies aimed to identify molecular markers retrieved
from tumor tissue while the relevance of blood-based biomarkers is less stringent assessed. MicroRNAs are currently
under investigation to serve as blood-based biomarkers. To date, no screening approach to identify relevant
miRNAs as biomarkers in blood of patients with rectal cancer was undertaken. The aim of the study is to investigate
the role of circulating miRNAs as biomarkers in those patients included in the TiMiSNAR Trial (NCT 03465982). This is
a biomolecular substudy of TiMiSNAR Trial (NCT03962088).
Methods: All included patients in the TiMiSNAR Trial are supposed to undergo blood collection at the time of
diagnosis, after neoadjuvant treatment, after 1 month from surgery, and after adjuvant chemotherapy whenever
indicated.
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Discussion: TiMiSNAR-MIRNA will evaluate the association of variation between preneoadjuvant and
postneoadjuvant expression levels of miRNA with pathological complete response. Moreover, the study will
evaluate the role of liquid biopsies in the monitoring of treatment, correlate changes in expression levels of miRNA
following complete surgical resection with disease-free survival, and evaluate the relation between changes in
miRNA during surveillance and tumor relapse.
Trial registration: Clinicaltrials.gov NCT03962088. Registered on 23 May 2019.
Keywords: Colorectal cancer, miRNA, Neoadjuvant treatment, Biomarkers, Translational research
Background
Neoadjuvant chemoradiotherapy (nCHT) followed by
surgery is the main treatment for locally advanced rectal
cancer, leading to significant decrease in tumor size
(downsizing) and a shift towards earlier disease stage
(primary tumor and lymph nodes involvement—down-
staging) [1]. As the response to nCHT is heterogeneous,
however, valid biomarkers are needed to monitor tumor
response [2–4]. Therefore, it is of high importance to
stratify and identify those patients, who can benefit from
an individualized targeted therapy. To date, a significant
number of studies aims to identify molecular markers
retrieved from tumor tissue while the relevance of
blood-based biomarkers is less stringent assessed.
Blood samples, i.e., liquid biopsy, indeed, offer several
advantages [5, 6]:
1. Taking blood samples is less invasive, less
expensive, easy to schedule, and nearly without any
severe complications.
2. Blood samples are a source of fresh DNA and RNA,
without modifications due to preservatives;
especially in the case of rectal cancer, beyond
intratumoral heterogeneity, tumor biopsies are in
general accompanied by normal, adenomatous, or
stromal tissue. This contamination may affect
results of molecular analyses
3. Investigating blood from patients can account for
molecular heterogeneity and surrogate for tumor
burden since tumor-derived fragments or bio-
markers are collected from all tumor cells in a pa-
tients’ body through circulation.
4. Liquid biopsy may offer both the possibility of
dynamic monitoring under treatment and the
possibility to assess disease activity even after
pathologic complete response (pCR) or after
resection of the tumor when no tissue is left for
molecular analyses.
Carcinoembryonic antigen (CEA) is, to date, estab-
lished as a colorectal cancer (CRC)-related tumor
marker, but its unsuitability as a screening and prognos-
tic marker has been demonstrated [7]. Circulating tumor
DNA (ctDNA) represents, nowadays, the main approach
to monitor tumor burden and therapy resistance, to
evaluate the presence of residual disease after potentially
curative treatment, and to monitor disease recurrence
with high sensitivity and specificity [8].
MicroRNAs (miRNAs) are currently under investi-
gation to serve as blood-based biomarkers as a poten-
tial alternative to CEA and ctDNA. miRNAs are
small, noncoding RNAs that regulate gene expression
by post-transcriptional mRNA binding, which pro-
motes the destabilization of target miRNAs. They are
highly conserved between species, stable, and easily
detectable even in small concentrations and have been
widely analyzed in physiological and pathological pro-
cesses, and their expression is tissue specific [9–11].
miRNA genes often have multiple transcription start
sites, and the promoters of intronic miRNAs are
sometimes distinct from the promoters of their host
genes [11, 12]. miRNA biogenesis process follows two
steps: a nucleic and a cytoplasmatic phase. In nucleus,
miRNAs are transcribed in primary-microRNAs by
RNA polymerase II and this process is controlled by
RNA Pol II-associated transcription factors and epi-
genetic regulators [12, 13]. Further, they are processed
by Drosha RNase III endonuclease in shorter stem
loops of about 60–70 nucleotides in length, called
pre-miRNAs [13]. Pre-miRNAs are then transported
from the nucleus to the cytoplasm via Exportin 5 and
processed in mature miRNAs by RNase III endo-
nuclease Dicer [14–17]. Further, maturation of miR-
NAs is carried out by the RISC-loading complex
(RNA-induced silencing complex) [18]. miRNAs con-
stitute the largest class of gene regulation and are in-
volved in all developmental processes, including stem
cell and germline maintenance, development and dif-
ferentiation, transcriptional and post-transcriptional
gene silencing, and subcellular localization [19, 20].
miRNAs regulate gene expression through the degrad-
ation of mRNA transcripts of their target genes and
the translation regulation of mRNA transcript without
RNA degradation [21].
Expression patterns of miRNA can be developmental
stage specific or, in other circumstances, tissue and site
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specific. The target specificity of miRNAs is largely pre-
determined by their so-called seed-sequence (containing
nucleotides at positions 2–7 of the miRNA).
It is well-known that miRNA is present in blood, but
its lability and the presence of ribonuclease in the
plasma raised some questions about how miRNA is car-
ried in the blood flow and its detectability [22, 23], sug-
gesting a mechanism of protection against ribonuclease
degradation.
One of the protecting mechanisms that have been sug-
gested is that extracellular RNA is bound with DNA [24],
but it has been excluded afterwards [25]. Another mech-
anism of RNA release that has been at first postulated was
cell death like apoptosis or mechanical stress in which
apoptotic bodies [26] containing miRNAs are released in
the blood flow, thus protecting them from Rnase degrad-
ation [27]. It is well-known also that most cell types re-
lease continuously soluble factors and exfoliate
membrane-derived vesicles into the extracellular space
[28]. These kind of vesicles are called exosomes and are
distinctly different from apoptotic bodies. Exosomes are
nanovesicles that are involved in cell-to-cell communica-
tion and regulation of different biological processes [29].
In recent years, exosomes have emerged being involved in
both physiological processes, such as immune response
and neuronal function, and also in the development and
progression of disease, such as cancer [30–32].
Exosomes can facilitate intercellular communication
through transportation of grown factors and miRNAs
and other small molecules, constituting the probable
mechanism of miRNA transportation and protection
against degradation [33, 34]. RNA has been found, in-
deed, on cancer cell surface, and it has been also found
in vesicles shed in vitro from a human colon adenocar-
cinoma cell line [35]. Cancer cells have been demon-
strated to secrete high quantity of exosomes than
normal cells [33, 34], and exosomal miRNAs are sup-
posed to play an important role in cancer cell prolifera-
tion, angiogenesis, metastasis, drug resistance, and
tumor inhibition [36–41]; some studies have shown the
role of exosomal miRNAs in cellular pathways from life
to death, from metabolism to communication [35]. Phe-
notypes of tumors, indeed, have been demonstrated de-
pending not only on cancer cells but also on
surrounding tumor microenvironment [42]. Cancer-cell
derived exosomes-miRNAs contribute to the recruit-
ment and reprogramming of constituents associated
with tumor environment, modifying the extracellular
matrix, reprogram functions of immunologically active
factor and immune target cells [43]. To date, four mech-
anisms are known through which miRNAs influence
tumor microenvironment: (1) self-modulation through
which less aggressive cancer cells receive exosomal miR-
NAs delivered by more aggressive cancer cells [44, 45];
(2) distant communication with other cells in the tumor
microenvironment for preparing a distant site of tumor
proliferation (metastasis-inducing mechanism by down-
regulation of tight junctions and endothelial monolayers
destruction) [46, 47]; (3) miRNAs from normal cells that
can alter the behavior of tumor cells [48]; and (4) viral
infection that stimulates secretion of exosomes with ab-
errant miRNAs inducing normal cells in a pre-tumoral
condition [49].
Based on these findings, miRNA detection in plasma
can play a crucial prognostic role from initial to develop-
mental phase of tumorigenesis and tumor progression,
with a fascinating possibility for personalized tumor
therapy [50, 51].
To date, no screening approach to identify relevant
miRNAs as biomarkers in blood of patients with rectal
cancer has been undertaken.
Methods/design
The Timing To Minimally Invasive Surgery After Neo-
adjuvant Chemoradiotherapy For Rectal Cancer: A Mul-
ticenter Randomized Controlled Trial - Biomarkers
Substudy is an observational prospectically design study
on the evaluation of the circulating miRNA in serum.
All included patients in the TiMiSNAR Trial (already
approved by local Ethical Committees on 8/5/2018) are
supposed to undergo blood collection at the time of
diagnosis, 1 month after neoadjuvant treatment, 1 month
after surgery, and at 1, 3, 6, and 12 months during adju-
vant chemotherapy (based on therapy protocol), when-
ever indicated or at 1, 3, 6 and 12months during
surveillance (Fig. 1).
An informed consent to participate has been prepared
and will be obtained by all the participants and collected
by the Principal investigator (Dr. Igor Monsellato).
Vacutainer tube will be addressed by a unique code of-
fered by a computer software. The study will take place
in community clinics and academic hospitals.
miR-17, miR-18b, miR-20a, miR-31, and miR-193a_3p,
miR-125b, miR-345, miR-154, miR-409-3p, miR-127-3p,
miR-214, miR-299-5p and miR-125b, miR-33a, miR-30e,
miR-338-3p, miR-200a and miR-378 expression levels will
be evaluated during multimodal therapy [1, 2, 52, 53].
Plasma sample collection
Fifteen milliliters of whole blood samples are collected
in Vacutainer tubes with spray-coated K2EDTA and
stored at room temperature. Blood undergoes centrifu-
gation for plasma separation within 2 h, to minimize the
hemolysis and nucleic acid degradation.
Tubes are subjected within 1 h to a first centrifugation
step at 2200×g for 15 min at room temperature. Plasma
supernatants are transferred to 15-mL tubes, carefully
avoiding contact with the lymphocytic ring, and tubes
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are centrifuged a second time at 3000×g and RT for 10
min to remove cellular debris.
Plasma samples are then collected into 1.5-mL cryo-
vials, and all the aliquots are stored at − 80 °C.
Plasma RNA extraction
Total RNA, including miRNAs, is isolated using a com-
mercial kit (miRNeasy Mini Kit, Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
RNA concentration is assessed using a spectrophotom-
eter. Adequate RNA concentration for mRNA expres-
sion is ≥ 30 ng/μL, and its quality is acceptable if the
ratio between the value of the absorbance (A) at 260 nm
and the absorbance at 280 nm is ≥ 1.8 and the ratio be-
tween the value of absorbance (A) at 260 nm and the
one at 230 nm is ≥ 2.
miRNAs expression assay
The nCounter miRNA Expression Assay (NanoString
Technologies, Seattle, WA, USA) is designed to provide
an ultra-sensitive, reproducible, and highly multiplexed
method for detecting miRNAs in total RNA across all
biological levels of expression. The assay provides a
method for detecting miRNAs without the use of reverse
transcription or amplification by using molecular bar-
codes called nCounter Reporter Probes. The assay can
be run on total RNA isolated from liquid biopsy.
Sample preparation involves a multiplexed annealing
of the specific tags to their target miRNA, a ligation re-
action, and an enzymatic purification to remove the
unligated tags. Sequence specificity between each
miRNA and its appropriate tag is ensured by careful,
stepwise control of annealing and ligation temperatures.
Control RNA included in the nCounter miRNA Sample
Preparation Kit allows the user to monitor the ligation
efficiency and specificity through each step of the
reaction.
NanoString technology is based on the direct molecu-
lar barcoding and digital detection of target miRNAs
using a color-coded probe pair. The probe pair consists
of a Reporter Probe, which carries the signal on its 5′
end, and a Capture Probe, which carries a biotin on its
3′ end. The complexity of the color codes, comprised of
four colors in six positions, allows a large diversity of
targets present in the same sample to be individually re-
solved and identified during data collection.
After hybridization, excess probes are washed away
using a two-step magnetic bead-based purification.
Magnetic beads derivatized with short nucleic acid se-
quences that are complementary to the Capture Probe
and the Reporter Probes are used sequentially. First, the
hybridization mixture containing target/probe com-
plexes is allowed to bind to magnetic beads complemen-
tary to sequences on the Capture Probe. Wash steps are
Fig. 1 SPIRIT figure
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performed to remove excess Reporter Probes and non-
target cellular transcripts. After washing, the Capture
Probes and target/probe complexes are eluted off the
beads and are hybridized to magnetic beads complemen-
tary to sequences on the Reporter Probe. An additional
wash is performed to remove excess Capture Probes. Fi-
nally, the purified target/probe complexes are eluted off
the beads and immobilized on the cartridge for data col-
lection. Data are analyzed using the nSolver™ software or
other analysis programs.
Primary endpoint
To evaluate the association of variation between pre-
neoadjuvant and postneoadjuvant expression levels of
miRNA with response to treatment.
Secondary endpoints
a) To evaluate the role of liquid biopsies in the
monitoring of treatment
b) To correlate changes in expression levels of miRNA
following complete surgical resection with disease-
free survival
c) To evaluate the relation between changes in
miRNA during surveillance and tumor relapse
Data analysis
Patient subpopulation for the analysis is formed by
the eligible patients with surgical evaluation and avail-
ability of plasma sample for the requested RNA
analyses.
Baseline characteristics will be described for overall
sample population by means of standard summary statis-
tics (absolute frequencies, mean median and extreme
values for continuous data, percentage for categorical
data).
The association of variation between preneoadjuvant
and postneoadjuvant expression levels of miRNA with
treatment response will be presented with contingency
tables and analyzed by mean of a logistic model. The
odds ratio for the association and the AUC will be calcu-
lated, together with the corresponding 95% confidence
intervals.
For secondary objectives (a) and (c), the role of liquid bi-
opsies in the monitoring of treatment will be investigated
by using a semi-parametric survival model (Cox model)
with time-dependent variables, in order to incorporate
modifications in the plasma measurements over time and
their association with outcome, while for objective (b) the
same analysis will be applied only on the subgroup of pa-
tients achieving pCR.
Discussion
Mechanisms behind the recurrence/metastatic process in
CRC are still not fully understood [52]. An important chal-
lenge in medical oncology is to identify patient or tumor
characteristics to be correlated to the response to neoadju-
vant and adjuvant treatment. Response variety of that im-
plies an individualized treatment approach [52–54]. A new
targeted approach to disease has been advocated for pre-
vention and treatment based on individual characteristics
regarding the environment, genes, lifestyle, and individual
risk factors [4, 5, 53, 54].
MicroRNAs (miRNAs) are small, noncoding sequences
that are post-transcriptional regulators of gene expression;
depending on the genes they regulate, miRNAs can function
as either oncogenes or tumor suppressors. In 2011, Della
Vittoria Scarpati et al., showed their first results on miRNA
evaluation in tissues as biomarkers for tumor response after
neoadjuvant treatment on 38 patients. They found that two
miRNAs (miR-630 and miR-622) were upregulated in all pa-
tients of group A (pathologic complete response) and down-
regulated in all patients of group B (all responses except
complete) (sensitivity and specificity: 100%) [55].
In 2017, Jo et al. published their results of the ana-
lysis on circulant miRNA on 17 rectal cancer affected
patients. All miRNAs that were retrieved from the
group of upregulated miRNAs in the tumor showed a
trend towards a reduced expression in the plasma of
rectal cancer patients compared to the control sam-
ples. Expression levels of miRNAs in the plasma that
were selected based on a decreased expression in the
tumor compared to the mucosa were irregularly up-
or downregulated miRNAs. They concluded that miR-
30c and 31 may have a potential relevance as
biomarker in rectal cancer to distinguish between
cancer and non-cancer patients in the plasma [2]. As
we stated before, based on findings by Jo et al., D’An-
gelo et al., and Yu et al., miR-17, miR-18b, miR-20a,
miR-31, and miR-193a_3p, miR-125b, miR-345, miR-
154, miR-409-3p, miR-127-3p, miR-214, miR-299-5p
and miR-125b, miR-33a, miR-30e, miR-338-3p, miR-
200a and miR-378 expression levels will be evaluated
during multimodality therapy [1, 2, 51].
Comparing miRNA levels in all steps of the treat-
ment with tumor response and finally with disease re-
lapse and postoperative and oncologic outcome, we
argue that miRNA could help to select patients who
can or cannot benefit from surgery or from neoadju-
vant alone in a setting of organ preservation, or from
adjuvant treatment.
Trial status
Protocol Version: V3.18 11/28/2018. Recruitment starting
date: 3/25/2019. Recruitment ending date: 3/25/2022.
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